Yissum - Research Development Company of the Hebrew University

Enhanced Nasal Drug Administration to Brain by a New Nanotechnology: The Phospholipid Magnesome

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Enhanced Nasal Drug Administration to Brain by a New Nanotechnology: The Phospholipid Magnesome
Project ID : 6-2018-6687

Yissum - Research Development Company of the Hebrew University

Description of the technology

Categories:

Life Science & Biotechnology, Nanotechnology

Technology Keywords:

Nasal delivery, CNS, quick onset,

peptides ,brain

Development Stage:

Formulations, results in animal

Patent Status:

WO/2019/049145

Highlights

We have designed and developed formulations based on a new nano-vesicular carrier containing Magnesium- the Phospholipid Magnesome.This drug delivery nanotechnology was tested in animal models. Results show enhanced efficacy versus controls.

Key Features

  • Improved delivery into the brain – quick onset
  • Better bioavailability by nasal route than by oral or subcutaneous routes
  • Particularly important in crisis management of pain, Parkinson rigidity, multiple sclerosis, Alzheimer, insomnia, glioma, sleepiness (EDS), epileptic seizures, hyperglycaemia, hypoglycaemia, hot flushes, emesis,
  • Carrier ingredients already have FDA approval.
  • Increase patient compliance - needle-free alternative for delivering drugs for acute and chronic conditions, allowing self-medication.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Elka Touitou
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • cns
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.